CORONA Remedies to Participate in Emkay and Equirus Investor Conferences
CORONA Remedies Limited officials will attend investor conferences organized by Emkay Global on August 13, 2026, and Equirus on August 14, 2026, both in Mumbai. The meetings will be in-person and based on publicly available information.
This is a standard disclosure regarding participation in investor events. No material new information is being shared, and the impact on the company's stock is expected to be minimal.
The announcement is a routine intimation of participation in investor conferences and does not contain any new financial or business performance information that would sway sentiment.
CORONA Remedies Limited announced its participation in two upcoming investor conferences. On Thursday, August 13, 2026, starting at 10:00 AM IST, company officials will attend the Emkay Global Investor Conference in Mumbai. This will involve group and one-on-one meetings conducted in person.
Following this, on Friday, August 14, 2026, also from 10:00 AM IST onwards, the company's officials will participate in the Equirus Investor Conference, also held in Mumbai and in person. Discussions during these conferences will be based solely on publicly available information, with no unpublished price-sensitive information to be shared.
The company also noted that the schedule for these events may be subject to change due to unforeseen circumstances. This intimation is available on CORONA Remedies' official website, www.coronaremedies.com.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.